MARKET

ARWR

ARWR

Arrowhead Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

44.51
-0.64
-1.42%
After Hours: 44.51 0 0.00% 17:42 07/10 EDT
OPEN
45.28
PREV CLOSE
45.15
HIGH
45.85
LOW
44.42
VOLUME
728.02K
TURNOVER
--
52 WEEK HIGH
73.72
52 WEEK LOW
19.51
MARKET CAP
4.53B
P/E (TTM)
450.05
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ARWR stock price target is 62.10 with a high estimate of 81.00 and a low estimate of 29.00.

EPS

ARWR News

More
What Kind Of Shareholders Hold The Majority In Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares?
Simply Wall St. · 1d ago
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis
Business Wire · 1d ago
Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Third Quarter Results
Business Wire · 2d ago
Here's Why Arrowhead Pharmaceuticals Stock Jumped 34% in June
Motley Fool · 2d ago
XBI: Not Everybody Can Be A Hero
Seeking Alpha - Article · 2d ago
Arrowhead Pharmaceuticals Is A Long-Term Investment To Consider
Seeking Alpha - Article · 06/29 05:21
An Evolving Portfolio Strategy
Seeking Alpha - Article · 06/18 23:40
Is Arrowhead Pharmaceuticals Inc. (ARWR) A Good Stock To Buy?
Insider Monkey · 06/17 02:46

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About ARWR

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.
More

Webull offers kinds of Arrowhead Pharmaceuticals Inc stock information, including NASDAQ:ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARWR stock methods without spending real money on the virtual paper trading platform.